<DOC>
	<DOC>NCT00632749</DOC>
	<brief_summary>Investigation of maximum tolerated dose, safety, efficacy and pharmcokinetics of BI 811283 in combination with cytarabine (LD-Ara-C) in previously untreated acute myeloid leukaemia (AML) patients</brief_summary>
	<brief_title>BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Inclusion criteria: Male or female adult with previously untreated acute myeloid leukaemia (AML) Confirmed diagnosis of AML according to the WHO definition (except for acute promyelocytic leukaemia, APL) Patient is considered ineligible for intensive treatment Patient is eligible for lowdose cytarabine (LDAraC) treatment Life expectancy &gt; 3 months Eastern cooperative oncology group (ECOG, R010787) performance score &lt;=2 at screening Signed written informed consent consistent with international conference on harmonisation good clinical practice (ICHGCP) and local legislation Exclusion criteria: Patient with APL (AML subtype M3 according to the FrenchAmericanBritish (FAB) classification). Relapsed or treatment refractory AML. Hypersensitivity to one of the trial drugs or the excipients. Other malignancy requiring treatment. Known central nervous system involvement. Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (ULN). INR &gt; 1.5 x ULN for subjects not on therapeutic vitamin K antagonists (phenprocoumon, warfarin). Bilirubin greater than 1.5 mg/dl. Serum creatinine greater than 2.0 mg/dl. LVEF (Left ventricular ejection fraction) &lt; 50% in echocardiography or clinical congestive heart failure New York Heart Association (NYHA) grade III or IV. Concomitant intercurrent illness, which would compromise the evaluation of efficacy or safety of the trial drug, e.g. active severe infection, unstable angina pectoris or cardiac arrhythmia. Psychiatric illness or social situation that would limit compliance with trial requirements. Concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug (i.e. other chemo or immunotherapy, see also section 4.2.2). Contraindications for cytarabine treatment according to the summary of product characteristics (SPC). Patients who are sexually active and unwilling to use a medically acceptable method of contraception during the trial (hormonal contraception, intrauterine device, condom with spermicide, etc.). Pregnant or nursing female patients. Patient unable to comply with the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>